Clinical Trial

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)

Study acronym: OTIMAS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls.
Trial Details
NCT Number NCT07376317
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma, Stage IV Melanoma
Enrollment 29 participants
Start Date 2021-12-10
Primary Completion 2027-01-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-29